Science in neo-Victorian poetry

This article considers the work of three contemporary poets and their engagement, in verse, with Victorian science. Beginning with the outlandish ‘theories’ of Mick Imlah’s ‘The Zoologist’s Bath’ (1983), it moves on to two works of biografiction – Anthony Thwaite’s poem ‘At Marychurch’ (1980), which outlines Philip Henry Gosse’s doomed attempts to unite evolution and Christianity, and Ruth Padel’s Darwin: A Life in Poems (2009). Starting off with John Glendening’s idea that science in neo-Victorian fiction, if fully embraced, provides an opportunity for self-revelation to characters, this article explores the rather less happy resolutions of each of these poems, while in addition discussing the ways in which these poems perform the formal changes and mutability discussed within them

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)

Description of a new genus and six new species of saurian reptiles

Volume: 6Start Page: 344End Page: 34

XXX.—Descriptions of two new birds from Jamaica

Volume: 3Start Page: 257End Page: 25

On the habits of Mabouya agilis

Volume: 3Start Page: 307End Page: 31

XXVI.—On the insects of Jamaica

Volume: 1Start Page: 268End Page: 27

XXIV.—On keeping marine animals and plants alive in unchanged sea-water

Volume: 10Start Page: 263End Page: 26

On the habits of Cyclura lophoma, an iguaniform lizard

Volume: 4Start Page: 64End Page: 6

XVIII.—On the chylaqueous fluid in the Actinoida

Volume: 1Start Page: 172End Page: 17